Effect of oxygen supplement during hemodialysis on serum erythropoietin and hemoglobin in end stage renal disease patient

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20161230004

Enrollment

Registered

2016-12-30

Start date

2016-08-16

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End&#45

Interventions

oxygen supplement FiO2 0.44 (cannula 6 LPM) for 4 hours 3 times per week for 2 weeks ,none

Experimental Device,No Intervention No treatment

oxygen supplement,none

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1) End-stage renal disease patients who had regular hemodialysis at King Chulalongkorn memorial hospital 2) Age older than 18 years 3) Stable erythropoietin supplement at least 2 months

Exclusion criteria

Exclusion criteria: 1) Gastrointestinal bleeding in 3 months 2) Chronic lung diseases

Design outcomes

Primary

Measure	Time frame
erythropoietin 6 weeks erythropoietin level	—

Secondary

Measure	Time frame
anemia 6 weeks hemoglobin, reticulocyte count	—

Contacts

Public ContactKullaya Takkavatakarn

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026